Institution
Royal Adelaide Hospital
Healthcare•Adelaide, South Australia, Australia•
About: Royal Adelaide Hospital is a healthcare organization based out in Adelaide, South Australia, Australia. It is known for research contribution in the topics: Population & Gastric emptying. The organization has 5830 authors who have published 10241 publications receiving 347876 citations. The organization is also known as: Adelaide Hospital & RAH.
Topics: Population, Gastric emptying, Transplantation, Medicine, Cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Alteplase was non-significantly associated with lower infarct growth and significantly associated with increased reperfusion in patients who had mismatch, and phase III trials beyond 3 h after treatment are warranted.
Abstract: Summary Background Whether intravenous tissue plasminogen activator (alteplase) is effective beyond 3 h after onset of acute ischaemic stroke is unclear. We aimed to test whether alteplase given 3–6 h after stroke onset promotes reperfusion and attenuates infarct growth in patients who have a mismatch in perfusion-weighted MRI (PWI) and diffusion-weighted MRI (DWI). Methods We prospectively and randomly assigned 101 patients to receive alteplase or placebo 3–6 h after onset of ischaemic stroke. PWI and DWI were done before and 3–5 days after therapy, with T2-weighted MRI at around day 90. The primary endpoint was infarct growth between baseline DWI and the day 90 T2 lesion in mismatch patients. Major secondary endpoints were reperfusion, good neurological outcome, and good functional outcome. Patients, caregivers, and investigators were unaware of treatment allocations. Primary analysis was per protocol. This study is registered with ClinicalTrials.gov, number NCT00238537. Findings We randomly assigned 52 patients to alteplase and 49 patients to placebo. Mean age was 71·6 years, and median score on the National Institutes of Health stroke scale was 13. 85 of 99 (86%) patients had mismatch of PWI and DWI. The geometric mean infarct growth (exponential of the mean log of relative growth) was 1·24 with alteplase and 1·78 with placebo (ratio 0·69, 95% CI 0·38–1·28; Student's t test p=0·239); the median relative infarct growth was 1·18 with alteplase and 1·79 with placebo (ratio 0·66, 0·36–0·92; Wilcoxon's test p=0·054). Reperfusion was more common with alteplase than with placebo and was associated with less infarct growth (p=0·001), better neurological outcome (p Interpretation Alteplase was non-significantly associated with lower infarct growth and significantly associated with increased reperfusion in patients who had mismatch. Because reperfusion was associated with improved clinical outcomes, phase III trials beyond 3 h after treatment are warranted. Funding National Health and Medical Research Council, Australia; National Stroke Foundation, Australia; Heart Foundation of Australia.
942 citations
••
TL;DR: The Prague C & M Criteria have high overall validity for the endoscopic assessment of visualized Barrett's esophagus lengths.
924 citations
••
Peter MacCallum Cancer Centre1, University of Melbourne2, Sir Charles Gairdner Hospital3, University of Western Australia4, Queensland University of Technology5, University of Queensland6, Royal Brisbane and Women's Hospital7, University of Newcastle8, Monash University9, University of Sydney10, University of Adelaide11, Royal Adelaide Hospital12
TL;DR: PSMA PET-CT is a suitable replacement for conventional imaging, providing superior accuracy, to the combined findings of CT and bone scanning, andSubgroup analyses showed the superiority of PSMAPET-CT (area under the curve of the receiver operating characteristic curve 91% vs 59% [32% absolute difference; 28-35] for patients with pelvic nodal metastases, and 95% vs 74% [22%absolute difference; 18-26] for Patients with distant metastases).
913 citations
•
Royal Melbourne Hospital1, Florey Institute of Neuroscience and Mental Health2, John Hunter Hospital3, University of Alberta4, Cliniques Universitaires Saint-Luc5, Auckland City Hospital6, University of Melbourne7, Royal Brisbane and Women's Hospital8, University of Otago9, Royal Adelaide Hospital10, Flinders Medical Centre11, Royal Perth Hospital12, Southern General Hospital13
TL;DR: In this paper, Alteplase was shown to promote reperfusion and attenuate infarct growth in patients who have a mismatch in perfusion-weighted MRI (PWI) and diffusion weighted MRI (DWI).
905 citations
••
TL;DR: Preoperative chemoradiotherapy with cisplatin and fluorouracil does not significantly improve progression-free or overall survival for patients with resectable oesophageal cancer compared with surgery alone, and further assessment is warranted of the role of cheMoradiotherapy in patients with squamous-cell tumours.
Abstract: Summary Background Resection remains the best treatment for carcinoma of the oesophagus in terms of local control, but local recurrence and distant metastasis remain an issue after surgery. We aimed to assess whether a short preoperative chemoradiotherapy regimen improves outcomes for patients with resectable oesophageal cancer. Methods 128 patients were randomly assigned to surgery alone and 128 patients to surgery after 80 mg/m 2 cisplatin on day 1, 800 mg/m 2 fluorouracil on days 1–4, with concurrent radiotherapy of 35 Gy given in 15 fractions. The primary endpoint was progression-free survival. Secondary endpoints were overall survival, tumour response, toxic effects, patterns of failure, and quality of life. Analysis was done by intention to treat. Findings Neither progression-free survival nor overall survival differed between groups (hazard ratio [HR] 0·82 [95% CI 0·61–1·10] and 0·89 [0·67–1·19], respectively). The chemoradiotherapy-and-surgery group had more complete resections with clear margins than did the surgery-alone group (103 of 128 [80%] vs 76 of 128 [59%], p=0·0002), and had fewer positive lymph nodes (44 of 103 [43%] vs 69 of 103 [67%], p=0·003). Subgroup analysis showed that patients with squamous-cell tumours had better progression-free survival with chemoradiotherapy than did those with non-squamous tumours (HR 0·47 [0·25–0·86] vs 1·02 [0·72–1·44]). However, the trial was underpowered to determine the real magnitude of benefit in this subgroup. Interpretation Preoperative chemoradiotherapy with cisplatin and fluorouracil does not significantly improve progression-free or overall survival for patients with resectable oesophageal cancer compared with surgery alone. However, further assessment is warranted of the role of chemoradiotherapy in patients with squamous-cell tumours.
890 citations
Authors
Showing all 5858 results
Name | H-index | Papers | Citations |
---|---|---|---|
Nicholas J. Talley | 158 | 1571 | 90197 |
John E. Morley | 154 | 1377 | 97021 |
Timothy P. Hughes | 145 | 831 | 91357 |
Christopher Hill | 144 | 1562 | 128098 |
John D. Potter | 137 | 795 | 75310 |
Daniel Thomas | 134 | 846 | 84224 |
Neville Owen | 127 | 700 | 74166 |
Linda Partridge | 118 | 491 | 56738 |
Michael Horowitz | 112 | 982 | 46952 |
Robert J. Norman | 103 | 755 | 45147 |
Craig S. Anderson | 101 | 650 | 49331 |
Helen E. Heslop | 97 | 523 | 36292 |
Philip J. Barter | 96 | 466 | 56118 |
Charles G. Mullighan | 94 | 435 | 37925 |
Prashanthan Sanders | 93 | 676 | 34146 |